A Study of Tislelizumab and SX-682 in People With Pancreas Cancer

Full Title

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Kevin Soares’ office at 212-639-3195

Protocol
24-370
Phase
Phase II (phase 2)
Investigator
Kevin C. Soares
Co-Investigators
Vinod P. Balachandran
Eileen M. O'Reilly
Wungki Park
Diseases
Hepatobiliary › Pancreatic Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT05604560
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description